When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

For many lung cancer patients, the best treatment options involve checkpoint inhibitors. These immunotherapy drugs unleash a patient’s immune system against their disease and can yield dramatic ...

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately held immunotherapy company, today announced the presentation of encouraging data in non-small cell lung cancer (NSCLC) from the ...

Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer. This is an ASCO ...

For many lung cancer patients, the best treatment options involve checkpoint inhibitors. These drugs unleash a patient's immune system against their disease and can yield dramatic results, even in ...

Clinical benefit observed in majority of NSCLC patients who progressed on checkpoint inhibitor Anktiva™ (also called N-803) restored or enhanced activity of checkpoint therapy even in those who ...